


available at www.sciencedirect.com







Corrigendum

Corrigendum to 'The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine' [European Journal of Cancer 44 (2008) 2615–2622]

S. Lopatriello^{a,*}, D. Amoroso^b, S. Donati^b, O. Alabiso^c, L. Forti^c, A. Fornasiero^d, A. Smergo^d, A. Lalli^e, C. Iacono^f, A. Lucenti^f, L. D'Alonzo^g, C. Negrini^a

The authors would like it to be known that there is an overestimate of capecitabine arm costs in the above article. This overestimate is due to a wrong automatic distribution of the central venous catheter unit cost to all patients in the infusional therapy arm – also to those treated with capecitabine in association with chemotherapies. Only 6 out of 31 patients treated with capacecitabine in association had received a central venous catheter infusion.

This overestimation does not notably affect the results of the study. However, from the IHCS perspective, the mean total cost is ϵ 5668 per CAP patient (instead of ϵ 5781). Specifically, the mean cost related to the central venous catheter insertion is ϵ 27 per CAP patient (as opposed to ϵ 140.22).

From the hospital perspective, the mean total cost is ϵ 4319 per CAP patient (instead of ϵ 4688). Specifically, the mean cost related to the central venous catheter insertion is ϵ 89 per CAP patient (as opposed to ϵ 457.50).

^aPBE Consulting, 37121 Verona, Italy

^bMedical Oncology Unit, Versilia Hospital and Tuscany Tumor Institute, Lido di Camaiore, Lucca, Italy

^cMedical Oncology Unit, Azienda Ospedaliera-Universitaria Maggiore della Carita', Novara, Italy

^dMedical Oncology Unit, Ospedale Immacolata Concezione, Piove di Sacco, Padua, Italy

^eMedical Oncology Unit, Ospedale Maria SS d. Splendore, Giulianova, Teramo, Italy

^fMedical Oncology Unit, Azienda Ospedaliera 'Civile-Maria Paternò Arezzo', Ragusa, Italy

^gCM Pharma, CM Sistemi, Milan, Italy

DOI of original article: 10.1016/j.ejca.2008.08.010

^{*} Corresponding author: Tel.: +39 045 8008609; fax: +39 045 593049. E-mail address: stefania.lopatriello@pbe.it (S. Lopatriello). 0959-8049/\$ - see front matter © 2009 Elsevier Ltd. All rights reserved.